SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas

Sub Koom Woong, Hyun Kim Tae, Hwan Shin Kyung, Ryull Pyo Hong, Joo Young Kim, Yong Kim Dae, Myonggeun Yoon, Yong Park Sung, Ho Lee Dae, Sun Ryu Jun, Seok Jung Yoo, Hyun Lee Sang, Kwan Ho Cho

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background. Concurrent chemoradiotherapy is commonly used for locally advanced nasopharyngeal carcinoma (NPC). We retrospectively analyzed the clinical outcomes of simultaneous modulated accelerated radiotherapy (SMART) with concurrent chemotherapy. Methods. Between January 2003 and May 2005, 24 patients with stage IIB to IVB NPC underwent SMART encompassing 3 targets: gross tumor volume (GTV), high-risk subclinical disease (CTV1), and low-risk subclinical disease (CTV2). Daily fractions of 2.4, 2.15, and 1.9 Gy were delivered to GTV, CTV1, and CTV2 to a total dose of 64.8, 58.05, and 51.3 Gy in 27 fractions over 5.5 weeks, respectively. Fifteen patients received concurrent cisplatin (DDP group), and 9 received 5-fluorouracil plus cisplatin (FP group). Results. With a median follow-up of 26 months (range, 17-45 months), 3-year overall and local-, regional-, and distant-progression-free survivals were 96% and 93%, 87%, and 88%, respectively. Grade 3 acute mucositis and pharyngitis were observed in 16 (67%) and 14 (59%) patients, respectively. Severe acute mucositis (100% vs 47%) and pharyngitis (100% vs 34%) were more frequently observed in the FP group than the DDP group (p < .01). Conclusions. Despite short follow-up with a small number of patients, our preliminary results demonstrated encouraging local-regional control and survival at the cost of modest increase in treatment related toxicities. The total dose and fractionation scheme of SMART used in our study is feasible with no life-threatening or fatal complications. However, the administration of fluorouracil in addition to cisplatin during SMART was associated with increased acute and late toxicities, and it should be administered with caution.

Original languageEnglish
Pages (from-to)159-169
Number of pages11
JournalHead and Neck
Volume30
Issue number2
DOIs
Publication statusPublished - 2008 Feb 1
Externally publishedYes

Fingerprint

Radiotherapy
Cisplatin
Mucositis
Pharyngitis
Tumor Burden
Fluorouracil
Dose Fractionation
Chemoradiotherapy
Disease-Free Survival
Drug Therapy
Survival
Nasopharyngeal carcinoma
Therapeutics

Keywords

  • Nasopharyngeal carcinoma
  • Simultaneous modulated accelerated radiotherapy (SMART)
  • Survival
  • Toxicity
  • Tumor control

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Woong, S. K., Tae, H. K., Kyung, H. S., Hong, R. P., Kim, J. Y., Dae, Y. K., ... Cho, K. H. (2008). SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas. Head and Neck, 30(2), 159-169. https://doi.org/10.1002/hed.20667

SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas. / Woong, Sub Koom; Tae, Hyun Kim; Kyung, Hwan Shin; Hong, Ryull Pyo; Kim, Joo Young; Dae, Yong Kim; Yoon, Myonggeun; Sung, Yong Park; Dae, Ho Lee; Jun, Sun Ryu; Yoo, Seok Jung; Sang, Hyun Lee; Cho, Kwan Ho.

In: Head and Neck, Vol. 30, No. 2, 01.02.2008, p. 159-169.

Research output: Contribution to journalArticle

Woong, SK, Tae, HK, Kyung, HS, Hong, RP, Kim, JY, Dae, YK, Yoon, M, Sung, YP, Dae, HL, Jun, SR, Yoo, SJ, Sang, HL & Cho, KH 2008, 'SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas', Head and Neck, vol. 30, no. 2, pp. 159-169. https://doi.org/10.1002/hed.20667
Woong, Sub Koom ; Tae, Hyun Kim ; Kyung, Hwan Shin ; Hong, Ryull Pyo ; Kim, Joo Young ; Dae, Yong Kim ; Yoon, Myonggeun ; Sung, Yong Park ; Dae, Ho Lee ; Jun, Sun Ryu ; Yoo, Seok Jung ; Sang, Hyun Lee ; Cho, Kwan Ho. / SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas. In: Head and Neck. 2008 ; Vol. 30, No. 2. pp. 159-169.
@article{fef489533f0d41ea9445c9d8ee5bf09f,
title = "SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas",
abstract = "Background. Concurrent chemoradiotherapy is commonly used for locally advanced nasopharyngeal carcinoma (NPC). We retrospectively analyzed the clinical outcomes of simultaneous modulated accelerated radiotherapy (SMART) with concurrent chemotherapy. Methods. Between January 2003 and May 2005, 24 patients with stage IIB to IVB NPC underwent SMART encompassing 3 targets: gross tumor volume (GTV), high-risk subclinical disease (CTV1), and low-risk subclinical disease (CTV2). Daily fractions of 2.4, 2.15, and 1.9 Gy were delivered to GTV, CTV1, and CTV2 to a total dose of 64.8, 58.05, and 51.3 Gy in 27 fractions over 5.5 weeks, respectively. Fifteen patients received concurrent cisplatin (DDP group), and 9 received 5-fluorouracil plus cisplatin (FP group). Results. With a median follow-up of 26 months (range, 17-45 months), 3-year overall and local-, regional-, and distant-progression-free survivals were 96{\%} and 93{\%}, 87{\%}, and 88{\%}, respectively. Grade 3 acute mucositis and pharyngitis were observed in 16 (67{\%}) and 14 (59{\%}) patients, respectively. Severe acute mucositis (100{\%} vs 47{\%}) and pharyngitis (100{\%} vs 34{\%}) were more frequently observed in the FP group than the DDP group (p < .01). Conclusions. Despite short follow-up with a small number of patients, our preliminary results demonstrated encouraging local-regional control and survival at the cost of modest increase in treatment related toxicities. The total dose and fractionation scheme of SMART used in our study is feasible with no life-threatening or fatal complications. However, the administration of fluorouracil in addition to cisplatin during SMART was associated with increased acute and late toxicities, and it should be administered with caution.",
keywords = "Nasopharyngeal carcinoma, Simultaneous modulated accelerated radiotherapy (SMART), Survival, Toxicity, Tumor control",
author = "Woong, {Sub Koom} and Tae, {Hyun Kim} and Kyung, {Hwan Shin} and Hong, {Ryull Pyo} and Kim, {Joo Young} and Dae, {Yong Kim} and Myonggeun Yoon and Sung, {Yong Park} and Dae, {Ho Lee} and Jun, {Sun Ryu} and Yoo, {Seok Jung} and Sang, {Hyun Lee} and Cho, {Kwan Ho}",
year = "2008",
month = "2",
day = "1",
doi = "10.1002/hed.20667",
language = "English",
volume = "30",
pages = "159--169",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas

AU - Woong, Sub Koom

AU - Tae, Hyun Kim

AU - Kyung, Hwan Shin

AU - Hong, Ryull Pyo

AU - Kim, Joo Young

AU - Dae, Yong Kim

AU - Yoon, Myonggeun

AU - Sung, Yong Park

AU - Dae, Ho Lee

AU - Jun, Sun Ryu

AU - Yoo, Seok Jung

AU - Sang, Hyun Lee

AU - Cho, Kwan Ho

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Background. Concurrent chemoradiotherapy is commonly used for locally advanced nasopharyngeal carcinoma (NPC). We retrospectively analyzed the clinical outcomes of simultaneous modulated accelerated radiotherapy (SMART) with concurrent chemotherapy. Methods. Between January 2003 and May 2005, 24 patients with stage IIB to IVB NPC underwent SMART encompassing 3 targets: gross tumor volume (GTV), high-risk subclinical disease (CTV1), and low-risk subclinical disease (CTV2). Daily fractions of 2.4, 2.15, and 1.9 Gy were delivered to GTV, CTV1, and CTV2 to a total dose of 64.8, 58.05, and 51.3 Gy in 27 fractions over 5.5 weeks, respectively. Fifteen patients received concurrent cisplatin (DDP group), and 9 received 5-fluorouracil plus cisplatin (FP group). Results. With a median follow-up of 26 months (range, 17-45 months), 3-year overall and local-, regional-, and distant-progression-free survivals were 96% and 93%, 87%, and 88%, respectively. Grade 3 acute mucositis and pharyngitis were observed in 16 (67%) and 14 (59%) patients, respectively. Severe acute mucositis (100% vs 47%) and pharyngitis (100% vs 34%) were more frequently observed in the FP group than the DDP group (p < .01). Conclusions. Despite short follow-up with a small number of patients, our preliminary results demonstrated encouraging local-regional control and survival at the cost of modest increase in treatment related toxicities. The total dose and fractionation scheme of SMART used in our study is feasible with no life-threatening or fatal complications. However, the administration of fluorouracil in addition to cisplatin during SMART was associated with increased acute and late toxicities, and it should be administered with caution.

AB - Background. Concurrent chemoradiotherapy is commonly used for locally advanced nasopharyngeal carcinoma (NPC). We retrospectively analyzed the clinical outcomes of simultaneous modulated accelerated radiotherapy (SMART) with concurrent chemotherapy. Methods. Between January 2003 and May 2005, 24 patients with stage IIB to IVB NPC underwent SMART encompassing 3 targets: gross tumor volume (GTV), high-risk subclinical disease (CTV1), and low-risk subclinical disease (CTV2). Daily fractions of 2.4, 2.15, and 1.9 Gy were delivered to GTV, CTV1, and CTV2 to a total dose of 64.8, 58.05, and 51.3 Gy in 27 fractions over 5.5 weeks, respectively. Fifteen patients received concurrent cisplatin (DDP group), and 9 received 5-fluorouracil plus cisplatin (FP group). Results. With a median follow-up of 26 months (range, 17-45 months), 3-year overall and local-, regional-, and distant-progression-free survivals were 96% and 93%, 87%, and 88%, respectively. Grade 3 acute mucositis and pharyngitis were observed in 16 (67%) and 14 (59%) patients, respectively. Severe acute mucositis (100% vs 47%) and pharyngitis (100% vs 34%) were more frequently observed in the FP group than the DDP group (p < .01). Conclusions. Despite short follow-up with a small number of patients, our preliminary results demonstrated encouraging local-regional control and survival at the cost of modest increase in treatment related toxicities. The total dose and fractionation scheme of SMART used in our study is feasible with no life-threatening or fatal complications. However, the administration of fluorouracil in addition to cisplatin during SMART was associated with increased acute and late toxicities, and it should be administered with caution.

KW - Nasopharyngeal carcinoma

KW - Simultaneous modulated accelerated radiotherapy (SMART)

KW - Survival

KW - Toxicity

KW - Tumor control

UR - http://www.scopus.com/inward/record.url?scp=39149095974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149095974&partnerID=8YFLogxK

U2 - 10.1002/hed.20667

DO - 10.1002/hed.20667

M3 - Article

C2 - 17764088

AN - SCOPUS:39149095974

VL - 30

SP - 159

EP - 169

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 2

ER -